Clinical trials: Androgens
Metastatic Hormone-sensitive Prostate Cancer
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by…
- Trial name
- ARASEC (NCT05059236)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 31 sites in United States
- Volunteers
- 223 people
- Sponsor
- Bayer
Prostatic Neoplasms
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.
- Trial name
- NCT00121095
- Testing
- Samarium Sm-153 lexidronam + Docetaxel
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cytogen Corporation
Healthy Subjects, Androgen Deficiency
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males
This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses
- Trial name
- NCT00540553
- Testing
- GSK971086
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
This research trial studies biomarkers in bone marrow and blood samples from patients with prostate cancer treated with ketoconazole.
- Trial name
- NCT01275651
- Testing
- laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Comprehensive Lifestyle Improvement Program for Men With Prostate Cancer2 (CLIPP2)
This study is an investigator initiated clinical study. A prospective, single arm unblinded, open label study will be carried out to determine the feasibility of recruitment, retention and adherence of 36 prostate cancer…
- Trial name
- CLIPP2 (NCT04228055)
- Testing
- CLIPP2
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Arizona
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Metastatic Hormone-sensitive Prostate Cancer, Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
The purpose of this study is to investigate the clinical efficacy and safety of darolutamide combined with androgen deprivation therapy (ADT) and different dose-intensity docetaxel chemotherapy in the treatment of patients with…
- Trial name
- NCT07031258
- Testing
- Dose of docetaxel
- Volunteers
- 50 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metastatic Hormone-sensitive Prostate Cancer
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens.
- Trial name
- CHAARTED (NCT00309985)
- Testing
- androgen-deprivation therapy, docetaxel
- Where
- 343 sites in United States
- Volunteers
- 790 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer
Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding
During 3D-conformal external beam radiation therapy treatments for prostate cancer, the prostate gland moves. The purpose of this study is to determine whether the placement of a prostate immobilization device into the rectum…
- Trial name
- NCT00114985
- Testing
- Prostate Immobilization Device
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer…
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
- Trial name
- NCT04381832
- Testing
- Etrumadenant, Zimberelimab, Quemliclustat
- Where
- 19 sites in United States, Canada
- Volunteers
- 173 people
- Sponsor
- Arcus Biosciences, Inc.
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Metabolic Syndrome
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
This is a multi-centre, double-blind, randomized phase III trial comparing metformin to placebo in patients with advanced prostate cancer starting (or have recently started) androgen deprivation therapy (ADT).
- Trial name
- PRIME (NCT03031821)
- Testing
- Metformin
- Where
- 16 sites in Canada
- Volunteers
- 166 people
- Sponsor
- Canadian Urologic Oncology Group
Prostate Cancer
Working Out M0 Bipolar Androgen Therapy
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).
- Trial name
- WOMBAT (NCT06594926)
- Testing
- Testosterone Enanthate
- Where
- 12 sites in Australia
- Volunteers
- 69 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Congenital Adrenal Hyperplasia, Hypogonadotropic Hypogonadism
Growing up With the Young Endocrine Support System (YESS!)
Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out…
- Conditions
- Congenital Adrenal Hyperplasia, Hypogonadotropic Hypogonadism, Growth Hormone Deficiency, Combined Pituitary Hormone Deficiency
- Trial name
- YESS (NCT04252001)
- Testing
- YESS! game, Snake '97, Transition-toolkit
- Where
- 7 sites in Belgium, Netherlands and 2 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- dr. Laura C. G. de Graaff-Herder
Pre-Eclampsia
Androgens Level in the Third Trimester of Pregnancy in Patients With Preeclampsia
This study aims to compare between androgens level (serum total and free testosterone) in women with preeclampsia and normal ones in the third trimester of pregnancy (28-40 weeks).
- Trial name
- NCT02992145
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams Maternity Hospital
Prostatic Neoplasms
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
This study is for men who have prostate cancer and have failed local therapy or are not a candidate for prostatectomy or radiation therapy.
- Trial name
- NCT02560051
- Testing
- Doxorubicin, Ketoconazole, Docetaxel
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center, Houston
Metastatic Cancer, Prostate Cancer
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.
- Trial name
- NCT00079001
- Testing
- zoledronic acid, androgen deprivation therapy, GnRH agonist
- Where
- 241 sites in United States, Canada
- Volunteers
- 645 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This phase II trial is studying how well giving gossypol together with androgen ablation therapy works in treating patients with newly diagnosed metastatic prostate cancer.
- Trial name
- NCT00666666
- Testing
- AT-101, Bicalutamide, LHRH agent
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Assessment of Predictive Role of [11C] Choline PET/CT on Survival in Prostate Cancer Patients With Biochemical Failure Without Androgen Deprivation Therapy
Among all the patients who underwent PET/CT with choline at our Institute between 2004 and 2007 to restage the prostatic disease following biochemical recovery of the disease, in this retrospective study the patients previously…
- Trial name
- NCT06167824
- Where
- Italy
- Volunteers
- 302 people
- Sponsor
- IRCCS San Raffaele
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.